GlaxoSmithKline

The FDA accepted GSK's BLA for Blenrep in combination with bortezomib plus dexamethasone (BVd) and pomalidomide plus dexamethasone (BPd) for relapsed or refractory multiple myeloma, supported by Phase III DREAMM-7 and DREAMM-8 trials. Blenrep combinations showed clinically meaningful improvements in efficacy endpoints, with manageable side effects. The FDA action date is set for July 23, 2025.

Belantamab mafodotin's comeback, FDA approvals for subcutaneous daratumumab-hyaluronidase and expanded CAR T-cell products, and isatuximab-based quadruplet emerging as new standard for transplant-ineligible newly diagnosed multiple myeloma patients.

The FDA accepted a BLA for belantamab mafodotin (Blenrep) combinations with bortezomib and dexamethasone (BVd) and pomalidomide and dexamethasone (BPd) for multiple myeloma. Supported by phase 3 DREAMM-7 and DREAMM-8 trials, these combinations showed significant PFS improvements. The FDA target action date is July 23, 2025.

The article discusses the implementation of a Server-Side Rendering (SSR) service entry script, identified by the unique hash 'eb4d49c5e8c4cb1d73be', which is hidden within the body of the document.

FDA expanded approvals for RSV vaccines to high-risk young and middle-age adults, but CDC advisors have not yet recommended them. Physicians consider individual health conditions to determine vaccine benefits, with real-world data guiding decisions. Vaccines show protection in high-risk groups, boosting confidence in their efficacy.

Life sciences sector resilient despite challenges; significant investments in ADCs, CGTs, AI, and CDMOs. ADCs and CGTs driving growth, with China leading in clinical trials and innovation. AI transforming drug discovery and clinical trials. APAC region dominating clinical trials, especially in oncology. China's biopharma sector booming, attracting global investments. CDMOs adopting digital revolution and AI for agile manufacturing. BIOSECURE Act impacting Chinese biotech companies, benefiting Indian CDMOs.

DelveInsight's 'Graft versus host disease Pipeline Insight 2024' covers 60+ companies and 65+ pipeline drugs, including clinical and nonclinical stage products, with a focus on therapeutics assessment by product type, stage, route of administration, and molecule type. Key companies and promising therapies in development are highlighted.

The 2024 LogiPharma AI Report reveals AI's shift from a 'nice-to-have' to a strategic necessity in pharmaceutical supply chains, with over half of surveyed leaders expecting ROI within 2-3 years. AI optimizes inventory management, enhances cold chain logistics, and drives digital transformation, though data integration remains a challenge. The LogiPharma conference in 2025 will focus on AI's practical applications in the industry.

The antibiotics and antimycotics market is projected to reach $91.54 billion by 2031, driven by infectious disease prevalence and R&D initiatives. Key players include Pfizer, Novartis, and Sanofi. North America leads in revenue, with APAC expected to show highest growth.

GSK's Menveo, a fully liquid MenACWY vaccine, received EC approval for children from 2 years, adolescents, and adults, simplifying immunisation and offering comparable immunogenicity and safety to the lyophilised version. IMD, caused by bacterial serogroups A, C, W, and Y, can be fatal or lead to long-term complications, with higher risk in young children and young adults.